# The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.

> **NCT04886336** · — · UNKNOWN · sponsor: **National Cheng-Kung University Hospital** · enrollment: 250 (estimated)

## Conditions studied

- HBV

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04886336
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-04
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04886336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04886336, "The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04886336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*